

RECEIVED

FEB 11 2003
TECH CENTER 1600/2800

Form PTO-1449 (modified)

Atty. Docket No.
INRP:095USSerial No.
10/043,877

List of Patents and Publications for Applicant's

Applicant
Tapas Mukhopadhyay *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:
January 9, 2002Group:
1641

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,767,138	6/16/98	Camden	514	365	12/20/96
	A2	5,880,144	3/9/99	Camden	514	397	9/6/97
	A3	5,900,429	5/4/99	Camden	514	395	1/28/97
	A4	5,929,099	7/27/99	Camden	514	365	7/15/96
	A5	6,077,862	6/20/00	Camden	514	388	3/1/99
	A6	6,380,232 B1	4/30/02	Quada, Jr. <i>et al.</i>	514	388	9/26/00
	A7	6,407,131 B1	6/18/02	Quada, Jr. <i>et al.</i>	514	395	9/29/00
	A8	6,420,411 B1	7/16/02	Camden <i>et al.</i>	514	395	9/29/00

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B3	WO 00/41669	7/20/00	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C28	Albonico <i>et al.</i> , "Control strategies for human intestinal nematode infections," <i>Adv. Parasitol.</i> , 42:277-341, 1999.
	C29	Braithwaite <i>et al.</i> , "Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease," <i>Eur. J. Clin Pharmacol.</i> , 22:161-169, 1982.
	C30	Braithwaite <i>et al.</i> , "Cyst and host tissue concentrations of mebendazole in patients undergoing surgery for hydatid disease," <i>The Medical J. of Australia</i> , 2:383-384, 1983.
	C31	Bryceson <i>et al.</i> , "Bioavailability and tolerability of mebendazole in patients with inoperable hydatid disease," <i>Trans. of the Royal Soc. Of Tropical Med. And Hygiene</i> , 76:563-564, 1982.
	C32	Burgat-Sacaze <i>et al.</i> , "Bound residues of veterinary drugs: bioavailability and toxicological implications," <i>Ann. Rech. Vet.</i> , 13:277-289, 1981.

25256380.1

EXAMINER:

Brandon Fasth

DATE CONSIDERED:

6/9/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

RECEIVED

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

INRP:095US

10/043,877

List of Patents and Publications for Applicant's

Applicant

Tapas Mukhopadhyay *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

January 9, 2002

Group:

1641

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C33	Chiba <i>et al.</i> , "Improvement of dissolution and bioavailability for mebendazole, an agent for human echinococcosis, by preparing solid dispersion with polyethylene glycol," <i>Chem. Pharm Bull.</i> , 39(8):2158-2160, 1991.
	C34	Dawson and Watson, "The effect of dose form on the bioavailability of mebendazole in man," <i>Br. J. Clin Pharmac.</i> , 19:87-90, 1985.
	C35	Dawson <i>et al.</i> , "The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [³ H]-mebendazole," <i>Br. J. Clin Pharmac.</i> , 14:453-455, 1982.
	C36	Delatour and Richard, "Embryogenic and antimitotic properties of benzimidazole series," <i>Therapie</i> , 31:505-515, 1976, with English translation.
	C37	Delatour <i>et al.</i> , "Embryotoxic and antimitotic properties of parbendazole, mebendazole and cambendazole," <i>C R Acad Sci Hebd Seances Acad Sci D</i> , 282(5):517-518, 1976, with English translation.
	C38	Description of Vermox® (mebendazole), pp. 1442 From <i>Physicians' Desk Reference</i> , Janssen Pharmaceutica, c1998.
	C39	Edwards and Breckenridge, "Clinical pharmacokinetics of anthelmintic drugs," <i>Clin. Pharmacokinet.</i> , 15:67-93, 1988.
	C40	Elhajouji <i>et al.</i> , "Indication for thresholds of chromosome non-disjunction versus chromosome lagging induced by spindle inhibitors in vitro in human lymphocytes," <i>Mutagenesis</i> , 12:133-140, 1997.
	C41	Farghali and Masek, "Immunopharmacologic agents in the amelioration of hepatic injuries," <i>International J. of Immunopharmacology</i> , 20:125-139, 1998.
	C42	Galtier <i>et al.</i> , "Fasciola hepatica: mebendazole and thiabendazole pharmacokinetics in sheep," <i>Exp. Parasitology</i> , 79:166-176, 1994.
	C43	Kromer, "Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds," <i>Digestion</i> , 56:443-454, 1995.
	C44	Lapras and Delatour, "Antimitotic properties of some embryotoxic and teratogenic anthelmintics derived from benzimidazole," <i>Proceedings of the European Society of Toxicology</i> , 18:294-296, 1977, with English translation.

25256380.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
INRP:095USSerial No.
10/043,877

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Tapas Mukhopadhyay *et al.*

Filing Date:

January 9, 2002

Group:

1641

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C45	Lubega and Prichard, "Interaction of benzimidazole anthelmintics with Haemonchus contortus tubulin: binding affinity and anthelmintic efficacy," <i>Exp. Parasitol.</i> , 73:203-213, 1991.
	C46	Lubega and Prichard, "Specific interaction of benzimidazole anthelmintics with tubulin from developing stages of thiabendazole-susceptible and resistant Haemonchus contortus," <i>Biochem. Pharmacol.</i> , 41:93-101, 1991.
	C47	Michiels <i>et al.</i> , "The pharmacokinetics of mebendazole and flubendazole in animals and man," <i>Arch. Int. Pharmacodyn.</i> , 256:180-191, 1982.
	C48	Upton, "Pharmacokinetic interactions between theophylline and other medication (Part I)," <i>Clin. Pharmacokinet.</i> , 20:66-80, 1991.
	C49	Van Hummelen <i>et al.</i> , "Clastogenic and aneugenic effects of three benzimidazole derivatives in the in vitro micronucleus test using human lymphocytes," <i>Mutagenesis</i> , 10:23-29, 1995.


25256380.1

EXAMINER:

DATE CONSIDERED:

C/9/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

Atty. Docket No.
INRP:095USSerial No.
10/043,877

List of Patents and Publications for Applicant's

Applicant
Tapas Mukhopadhyay *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:
January 9, 2002Group:
1641

(Use several sheets if necessary)

U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A9	6,028,116	2/22/00	Sperl <i>et al.</i>	514	729	4/3/98
	A10	6,046,206	4/4/00	Pamukcu <i>et al.</i>	514	259	4/30/97
	A11	6,211,177 B1	4/3/01	Sperl <i>et al.</i>	514	241	11/24/98
	A12	6,262,059 B1	7/17/01	Pamukcu <i>et al.</i>	514	260	4/6/98
	A13	6,348,032 B1	2/19/02	Sperl <i>et al.</i>	574	338	11/23/98
	A14	6,369,092 B1	4/9/02	Pamukcu <i>et al.</i>	514	394	4/30/01

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25284725.1

EXAMINER:

DATE CONSIDERED:

6/9/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED

APR 25 2003

TECH CENTER 1600/2900